Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

Novartis Pharmaceuticals · 2027
ClinicalTrials.gov · Datasets · License: Public Domain · 2027
Open Source ↗
breast-cancer
pik3ca-related overgrowth spectrum (pros), breast neoplasms (including advanced or metastatic breast cancer with pik3ca mutation), alpelisib (byl719), pi3k inhibitor, pik3ca mutation, post-trial access, roll-over study, long-term safety, open-label, continued treatment access, solid tumors, breast cancer
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 872927
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.